Medicine and Dentistry
Radiation Therapy
99%
Metastatic Carcinoma
93%
Overall Survival
79%
Recurrent Disease
71%
Radiation Oncology
63%
Non Small Cell Lung Cancer
62%
Disease
57%
Malignant Neoplasm
53%
Prostate Cancer
52%
Brain Metastasis
45%
Stereotactic Body Radiation Therapy
39%
Stereotactic Radiosurgery
37%
Low Drug Dose
36%
Neuroinflammation
36%
C57BL/6
36%
Cancer Therapy
36%
Neck
33%
Drug Megadose
31%
Clivus
31%
Volumetric Modulated Arc Therapy
31%
Myeloid Cell
31%
Brain Radiation
31%
Image-Guided Radiation Therapy
31%
Radiation Injury
31%
Oral Cancer
31%
Chemokine Receptor
31%
Transplantation
31%
Hemangioma
31%
Laryngoscopy
31%
Hepatocellular Carcinoma
31%
Remote Sensing
31%
Cellular Infiltration
31%
Small Cell Lung Cancer
31%
Palliative Radiation Therapy
31%
Lung Cancer Survival
31%
Cancer Diagnosis
31%
T Cell
31%
Isocenter
31%
Cancer Registry
31%
Gamma Chemokine
31%
Radiosurgery
31%
Multiple Myeloma
31%
Hypofractionated Radiotherapy
31%
Skull Irradiation
31%
Polyethylene Terephthalate
31%
Systemic Therapy
28%
Sequela
23%
Hazard Ratio
23%
Multivariate Analysis
20%
Bivariate Analysis
20%
Keyphrases
Stereotactic Radiosurgery
100%
Brain Metastases
97%
Non-small Cell Lung Cancer (NSCLC)
75%
Overall Survival
68%
Intracranial Progression
62%
Multi-institutional Analysis
62%
Head-and-neck
48%
High Dose
46%
Stereotactic Body Radiotherapy
39%
Low-volume Metastasis
39%
C57BL
37%
Neuroinflammation
37%
Cancer Treatment
37%
Cancer Diagnosis
36%
Recurrence Pattern
35%
Synchronous Presentation
34%
Extracranial
34%
Cancer Registry
31%
Rectosigmoid Cancer
31%
Validation Studies
31%
Slit Ventricle
31%
Hypofractionated Radiation Therapy
31%
Stage Migration
31%
T Cell Infiltration
31%
Fiberoptic Laryngoscopy
31%
Small Cell Lung Cancer
31%
Simulation Workshop
31%
Survival Stage
31%
Infliximab
31%
Large Prostate
31%
Survival Improvement
31%
Prostate Volume
31%
Patients with Prostate Cancer
31%
Multidisciplinary Management
31%
CD11c
31%
Intraosseous Hemangioma
31%
Lung Cancer Survival
31%
Sarcoidosis
31%
Prognostic Model
31%
Mycophenolate Mofetil
31%
Voluntary Running
31%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
31%
Cranial Irradiation
31%
Mouse Brain
31%
Myeloid Cells
31%
Simultaneous Integrated Boost
31%
Clivus
31%
Ultra-low Dose
31%
Hippocampal Neurogenesis
31%
Oral Cavity Cancer
31%
